5 results about "Chemerin" patented technology

This application relates to the technical field of biomarkers, and in particular, to a biomarker for diagnosing central precocious puberty (CPP) in females and uses thereof. This application provides a biomarker for diagnosing CPP in females. The biomarker is one, two, or three of leptin, RBP4, or chemerin. Experiments performed in this application show that female children with CPP exhibit leptin, RBP4, and chemerin levels in peripheral blood significantly higher than those of healthy children, and that serum leptin and RBP4 levels in CPP patients change early during development of CPP, indicating that these three adipokines may participate in the development of CPP.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The present disclosure relates to among other things, an ophthalmic formulation of a lipidated chemerin composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof, that is stable in terms of pH, osmolality, physical appearance, and purity of the chemerin composition, when stored under normal storage conditions. One aspect of the present disclosure also relates to use of the said ophthalmic formulation for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain.

The present disclosure relates to RNAs and other polynucleotides encoding antigens, which can be used in vaccine compositions. In some examples, the RNA also encodes a chemical attractant, such as a chemokine, C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10), or C-X-C motif chemokine ligand 11 (CXCL11). The disclosure also relates to the use of the RNA and compositions in a method of inducing an immune response in a subject.